Encainide: Difference between revisions
(Created page with "==Administration== *Type: Class IC antiarrhythmic (sodium channel blocker) *Dosage Forms: Capsules (25mg or 35mg) *Routes of Administration: PO *Common Trade Names: Enkaid ==...") |
|||
| Line 15: | Line 15: | ||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Category B | ||
===Lactation risk=== | ===Lactation risk=== | ||
Revision as of 00:10, 27 June 2021
Administration
- Type: Class IC antiarrhythmic (sodium channel blocker)
- Dosage Forms: Capsules (25mg or 35mg)
- Routes of Administration: PO
- Common Trade Names: Enkaid
Adult Dosing
Sustained Ventricular Tachycardia
- 25mg PO t.i.d
- May be increased to 35mg PO t.i.d after 3-5 days
Pediatric Dosing
- Safety and effectiveness in pediatrics not established
Special Populations
Pregnancy Rating
- Category B
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Preexisting 2nd or 3rd-degree AV block
- Preexisting right bundle branch block w/ left hemiblock
- Presence of cardiogenic shock
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion: